The classical example for efficient use of a specific protein kinase inhibitor in the clinics is the Bcr-Abl kinase inhibitor STI-572 (Imatinib) used for the treatment of chronic myelogenic leukemia (CML) [123]. The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.